This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Parkinson's disease (PD)	Leucine-rich repeat kinase 2 (LRRK2)	Computational and <i>in vitro</i> studies identified a LRRK2 inhibitor that could be optimized to treat PD. High throughput screening, computational modeling and <i>in vitro</i> testing identified a lead diaminopyrimidine analog as a selective low nanomolar inhibitor of LRRK2. In normal mice, the compound showed good brain penetration. Future studies could include testing the compound in animal models of PD. <i>SciBX</i> 5(22); doi:10.1038/scibx.2012.579 Published online May 31, 2012	Patent and licensing status unavailable	Chen, H. <i>et al. J. Med. Chem.</i> ; published online May 16, 2012; doi:10.1021/jm300452p Contact: Dan Burdick, Genentech Inc., South San Francisco, Calif. e-mail: burdick.dan@gene.com Contact: Huifen Chen, same affiliation as above e-mail: chen.huifen@gene.com